[1] Partelli S, Javed AA, Andreasi V, et al.The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms[J]. Eur J Surg Oncol,2018,44(6):778-783.
[2] Fairweather M, Swanson R, Wang J, et al.Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database[J]. Ann Surg Oncol,2017,24(8):2319-2325.
[3] Hüttner FJ, Schneider L, Tarantino I, et al.Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis[J]. Langenbecks Arch Surg,2015,400(6):715-723.
[4] Le Treut YP, Grégoire E, Klempnauer J, et al.Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study[J]. Ann Surg,2013, 257(5):807-815.
[5] Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial Neuroendocrine Neoplasms (NEN) and NEN of unknown primary site[J]. Neuroendocrinology,2016,103(2):172-185.
[6] Cives M, Strosberg J.The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors[J]. Drugs,2015,75(8):847-858.
[7] Rinke A, Müller HH, Schade-Brittinger C, et al.Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group[J]. J Clin Oncol,2009,27(28):4656-4663.
[8] Wang Y, Wang W, Jin K, et al.Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors[J]. Oncol Lett,2017,13(3):1165-1174.
[9] Caplin ME, Pavel M, Ćwikła JB, et al.Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med,2014,371(3):224-233.
[10] Scarpa A, Chang DK, Nones K, et al.Whole-genome landscape of pancreatic neuroendocrine tumours[J]. Nature,2017,543(7643):65-71.
[11] Yao JC, Shah MH, Ito T, et al.Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med,2011, 364(6):514-523.
[12] Raymond E, Dahan L, Raoul JL, et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med,2011,364(6):501-513.
[13] Sorbye H, Welin S, Langer SW, et al.Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma(WHO G3): the NORDIC NEC study[J]. Ann Oncol,2013,24(1):152-160.
[14] Strosberg J, El-Haddad G, Wolin E, et al.Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors[J]. N Engl J Med,2017,376(2):125-135.
[15] Vanderwalde A, Spetzler D, Xiao N, et al.Microsatellite instability status determined by next-generation sequen-cing and compared with PD-L1 and tumor mutational bur-den in 11,348 patients[J]. Cancer Med,2018,7(3):746-756.
